Document:

Exhibit 10.1

ASSIGNMENT OF
LEASE AND ASSUMPTION AGREEMENT

AGREEMENT  (“Assignment”) made as of the 9th day of March, 2007, by and between NITROMED,
INC., a Delaware corporation (“Assignor”) and SHIRE HUMAN GENETIC
THERAPIES, INC., a Delaware corporation (“Assignee”).

W I T N E S S E T
H

WHEREAS, Assignor is the
tenant under that certain lease dated January 30, 2004, by and between Assignor
and Patriot Partners Lexington, LLC, as successor in interest to PM Atlantic
Lexington, LLC (the “Landlord”) as amended on March 9, 2007 (the “Lease”),
annexed hereto and made a part hereof pertaining to certain premises legally
described therein (the “Premises”), and

WHEREAS, capitalized
terms used herein without definition which are defined in the Lease shall have
the respective meanings ascribed to them therein.

NOW, THEREFORE, in
consideration of the sum of ten dollars ($10.00) and for other good and
valuable consideration, the mutual receipt and legal sufficiency of which is
hereby acknowledged, the parties hereto do hereby agree as follows:

1.             Assignor hereby assigns to Assignee the estate of
Assignor as tenant created by the Lease, together with: (a) all of Assignor’s
right, title and interest in, to and under the Lease and the documentation set
forth in Exhibit A attached hereto and the Premises demised thereby, which
Premises are more particularly described in the Lease; (b) any and all rights
to extend or renew the Lease; and (c) any and all other rights and options
granted to Assignor as the Tenant thereunder, to have and to hold the same unto
Assignee, its successors and assigns, from and after the “Effective Date” (as
that term is defined in Section 10 hereof).

2.             Assignee hereby accepts the assignment of the Lease and
the documentation set forth in Exhibit A attached hereto from Assignor
and hereby assumes the obligation to observe and perform all of the terms,
covenants and conditions thereof to be observed or performed by Assignor
thereunder from and after the Effective Date.

3.             Assignor shall remain liable for and will hold Assignee
harmless and indemnify Assignee against any and all claims and/or liabilities
arising from or in connection with the Lease prior to the Effective Date
hereof. Assignee shall be liable for and will hold Assignor harmless and indemnify
Assignor against any and all claims and/or liabilities arising from or in
connection with the Lease from and after the Effective Date hereof.

4.             Assignor represents and warrants that:

(a)           The Lease is in full
force and effect and is enforceable in accordance with its terms.  There exists no default or condition which,
with the giving of notice, the passage of 

time or both, could become a default by Assignor or,
to Assignor’s knowledge, by Landlord under the Lease.

(b)           Other than Assignor,
there are no parties in possession or parties having any current or future
right to occupy the Premises during the term of the Lease.

(c)           There exists no
material violation of any covenant, condition, restriction, easement, agreement
or order to which Assignor is a party or otherwise has knowledge affecting any
portion of the Premises.

(d)           The copy of the Lease attached hereto
as Exhibit A is a true and correct copy of the Lease, and there have been no
modifications or amendments to the Lease except as set forth in said Exhibit A.

5.             In connection with the assignment of the Lease from
Assignor to Assignee, the following terms and conditions shall apply:

(a)           On or before March
9, 2007, Assignor shall deliver possession of the Premises to Assignee in broom
clean condition with all of Assignor’s personal property removed therefrom and
with the Decommissioning Work (defined below) complete in all respects.  Notwithstanding this Assignment, Assignor
shall have the right to occupy approximately 11,000 square feet of office space
as set forth on the plan attached hereto as Exhibit A (the “Retained
Office Space”) until March 31, 2007.  If
Assignor fails to deliver possession of the Retained Office Space to Assignee
as aforesaid on or before April 1, 2007, then Assignor shall pay to Assignee
the amount of (i) $5,000.00 for each and every day that elapses after April 1,
2007, and (ii) $10,000 for each and every day that elapses after April 15,
2007, until Assignor delivers to Assignee possession of the Retained Office
Space in the condition required above. 
Without limitation of the foregoing, Assignor agrees that Assignee may
at any time after April 30, 2007, commence legal action against Assignor to
recover possession of the Retained Office Space.  Assignor and Assignee shall cooperate with
each other from the Effective Date through the Departure Date (as hereinafter
defined) so as to accommodate their shared occupancy of the Premises during
this period.

(b)           Assignor shall pay
for all utilities and other services used at the Premises until the date (the “Departure
Date”) that is the later to occur of March 31, 2007, and the date on which
Assignor actually delivers possession of the Retained Office Space to Assignee
in the condition required above.  All
utilities and other services from and after the Departure Date shall be at the
sole cost and expense of Assignee.

(c)           If Assignee occupies
and/or conducts its business operations within the Premises, i.e., as opposed
to preparing the Premises for Assignee’s occupancy, prior to July 1, 2007,
Assignee shall reimburse Assignor all Yearly Rent, Operating Expenses and Taxes
for the period commencing on the date that Assignee first occupies and/or
conducts business operations in the Premises. 
By way of example, if Assignee commences business operations within the
Premises on May 5, 2007, Assignee shall pay Assignor within five (5) days of
occupancy of the Premises, an amount equal to the sum of the Yearly Rent,
Operating Expenses and Taxes paid for the period commencing on May 5, 2007 and
ending June 30, 2007.

 2
 

 

(d)           Assignor shall
provide Assignee with copies of any permits Assignor obtained from the Town of
Lexington prior to its occupancy of the Premises.

(e)           On or before March
9, 2007, Assignor shall at its sole expense decommission the Premises in
accordance with all applicable laws and with the requirements set forth in
Exhibit B attached hereto (the “Decommissioning Work”).  If Assignor fails to complete such
Decommissioning Work on or before March 9, 2007, which failure continues for
more than twenty (20) days after notice to Assignor thereof, Assignee may, but
shall have no obligation to, complete such Decommissioning Work at Assignor’s
sole cost and expense.

(f)            Assignor hereby
assigns to Assignee all of Assignor’s right, title and interest in and to the
furniture, laboratory equipment, and other personal property listed on Exhibit
C  in its “as is” condition without
any representation or warranty on the part of Assignor except that Assignor
shall warrant to Assignee that Assignor has good and clear title to all such
property, the right to convey such property to Assignee and that all such
property shall be free and clear of all liens and claims of third parties in
and to such property or any of it.  On
the Effective Date, Assignor shall deliver to Assignee a bill of sale for such
property in the form of Exhibit D attached hereto.

(g)           On the Effective
Date, Assignor shall deliver to Assignee the amount of one million one hundred
sixty thousand two hundred and thirty seven dollars and eighty nine cents
($1,160,237.89) as consideration for Assignee’s assumption of the Lease.

(h)           On or before the
Effective Date, Assignee shall deliver to Landlord a Hazardous Waste Management
Program pursuant to Section 17.6 and Exhibit 7 of the Lease.

(i)            For purposes of
Section 26 of the Lease, the Assignee’s address shall be as follows:

Shire Human Genetics
Therapies, Inc.

700 Main Street

Cambridge, MA 02139

Attn:  Vice President, Facilities and
Engineering Operations

Shire Human Genetics
Therapies, Inc.

700 Main Street

Cambridge, MA 02139

Attn:  Legal Counsel

6.             All times set forth herein shall be of the essence.

7.             Assignor and Assignee each represent and warrant one to
the other that, except as may be hereinafter set forth, neither of them has
employed any broker in connection with the negotiations of the terms of this
Assignment or the execution hereof. 
Assignor and Assignee hereby agree to indemnify and to hold each other
harmless against any loss, expense or liability with respect to any claims for
commissions or brokerage fees arising from or out of any breach of the
foregoing representation and warranty. 
Each of Assignor and Assignee has employed as its broker Richards Barry
Joyce and Partners, LLC (the “Broker”). 
Assignor shall be responsible for any commission due Broker in
connection with this Assignment.

 3
 

 

8.             This Agreement shall be binding upon and shall inure to
the benefit of the parties hereto and their respective successors and assigns.

9.             Assignor and Assignee each represent and warrant to the
other that they have all requisite authority to enter into this Assignment and
to be bound by all terms and provisions set forth herein.  This Assignment is made pursuant to, and
shall be governed by, and construed in accordance with the laws of the Commonwealth
of Massachusetts.

10.           The Effective Date of this Agreement
shall be the date of delivery to Assignor and Assignee of the Landlord’s
Consent to this Assignment.

 4
 

 

IN WITNESS WHEREOF, the
parties hereto have executed this Agreement as an instrument under seal as of
the day and year first above written.

	
  

  	
  ASSIGNOR

  	
   

  
	
  WITNESS:

  	
  NITROMED, INC.

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  /s/ Matthew A.
  Ebert

  	
   

  	
  By 

  	
  /s/ James G. Ham, III

  	 

	
   

  	
  Name: James G. Ham, III

  	
   

  
	
   

  	
  Title: CFO

  	
   

  
	
   

  	
  thereunto duly authorized

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  ASSIGNEE

  	
   

  
	
  WITNESS:

  	
  SHIRE HUMAN GENETIC THERAPIES, INC.

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  /s/ Kelly
  Honohan

  	
   

  	
  By 

  	
  /s/ David D. Pendergast

  	 

	
   

  	
  Name: David D. Pendergast

  	
   

  
	
   

  	
  Title: President

  	
   

  
	
   

  	
  thereunto duly authorized

  	
   

  
							

 

 5

Exhibit A

Lease and Lease
Documentation

1.             Lease.

2.             Letter
Agreement dated February 3, 2004 regarding cosmetic work.

3.             Notice
of Lease dated January 30, 2004.

4.             Rent
Commencement Certificate dated July 15, 2004.

5.             Lehman
SNDA dated April 28, 2005.

6.             Lehman
Estoppel dated April 28, 2005.

 A-1
  

 

Exhibit B

Decommissioning Work

All decommissioning
activities will take place per relevant local, state and federal regulations
having jurisdiction. In the absence of an authority having jurisdiction,
appropriate measures will be taken per mutual agreement of the parties.  Assignor shall certify that all biological
materials, chemicals, acids, bases, reagents, radioactive isotopes, and other
hazardous and/or flammable materials have been removed from the premises.  Assignor shall certify that all surfaces,
such as but not limited to, biosafety cabinets, chemical fume hoods, chemical
storage cabinets, flammable storage cabinets, laboratory bench tops, and sink
traps, have been properly cleaned or replaced to remove any trace of such
hazardous materials as those mentioned above. Certification shall be in the
form of a signed affidavit from the agency or agencies that performed the
decommissioning services for the Assignor.

Assignor will reasonable
cooperate with Assignee to allow for review of documentation associated with
the decommissioning/decontamination work that is performed.  Assignor will also walk through the facility
with the Assignee to verify that the decommissioning services have been
completed successfully and to Assignee’s reasonable satisfaction and approval.

Assignor shall deliver to
Assignee all maintenance manuals in the possession of Assignor for all
laboratory and mechanical equipment remaining on the Premises.

 B-1

 

Exhibit C

Inventory of
Furniture and Equipment

	
  Offices

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Offices

  	
  Desks

  	
  File

  cabinets

  	
  Chairs

  Swivel

  	
  Non-

  Swivel

  	
  Tables

  
	
  1st floor

  	
  12

  	
  7

  	
  13

  	
  7

  	
  12

  	
  4

  
	
  2nd floor

  	
  42

  	
  38

  	
  76

  	
  38

  	
  38

  	
  3

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Cubicles

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Large

  Cubes

  	
  Small

  Cubes

  	
  Desks

  	
  File

  cabinets

  	
  Chairs

  Swivel

  	
   

  
	
  1st floor

  	
  0

  	
  5

  	
  5

  	
  10

  	
  5

  	
   

  
	
  2nd floor

  	
  5

  	
  31

  	
  36

  	
  67

  	
  36

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Conference Rooms

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Rooms

  	
  Tables

  	
  Non-

  Swivel

  	
   

  	
   

  	
   

  
	
  1st floor

  	
  2

  	
  12

  	
  26

  	
   

  	
   

  	
   

  
	
  2nd floor

  	
  3

  	
  0

  	
  0

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Lunch Room

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Rooms

  	
  Tables

  	
  Chairs

  	
   

  	
   

  	
   

  
	
  1st floor

  	
  1

  	
  14

  	
  47

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Break Room 

  	
  (in Animal Lab)

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Rooms

  	
  Tables

  	
  Chairs

  	
   

  	
   

  	
   

  
	
  1st floor

  	
  1

  	
  1

  	
  7

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Reception Desk

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Desk

  	
  Chairs

  	
   

  	
   

  	
   

  	
   

  
	
  1st floor

  	
  1

  	
  1

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

Laboratory
and Vivarium Equipment

All that certain equipment previously identified by
Assignee and Assignor as evidenced by tagging and labeling such equipment
previous to the date hereof.

 C-1

 

Exhibit D

Bill of Sale

This Bill of Sale is dated as of March 9, 2007 and is
executed and delivered by NitroMed, Inc., a Delaware corporation having a
principal business address at 125 Spring Street, Lexington, Massachusetts 02421
(the “Seller”), to Shire Human Genetic
Therapies, Inc., a Delaware corporation having a place of business at 700 Main
Street, Cambridge, Massachusetts 02139 (the “Buyer”).

WHEREAS,
pursuant to that certain Assignment of Lease and Assumption Agreement, dated as
of even date herewith, by and between Seller and Buyer (the “Agreement”),
Seller has agreed to sell, convey, assign, transfer and deliver to Buyer, and
Buyer has agreed to purchase and acquire, all of Seller’s right, title and
interest in and to the furniture, equipment and other assets of Seller listed
on Exhibit A attached hereto
(the “Assets”);

NOW, THEREFORE, in
consideration of the mutual promises set forth in the Agreement and for other
good and valuable consideration, the receipt of which is hereby acknowledged,
the Seller hereby agrees as follows:

1.     Seller hereby sells, conveys, assigns, transfers and delivers to
Buyer, its successors and assigns, all of Seller’s rights, title and interest
in and to the Assets.

2.     This sale, conveyance, assignment and transfer has been executed
and delivered by Seller in accordance with the Agreement and is expressly made
subject to any and all obligations and commitments which Buyer has expressly
agreed to perform and discharge pursuant to the Agreement.  Seller warrants to Buyer that Seller has good
and clear title to the Assets, the right to convey the Assets to Buyer and that
the Assets are free and clear of all liens and claims of third parties in and
to the Assets.

3.     The Seller, by its execution of this Bill of Sale, and Buyer, by
its acceptance of this Bill of Sale, each hereby acknowledges and agrees that
neither the representations and warranties nor the rights and remedies of the
Seller and Buyer under the Agreement shall be deemed to be enlarged,
diminished, modified or altered in any way by this instrument.

4.     This Bill of Sale shall be governed by and construed in
accordance with the internal laws of the Commonwealth of Massachusetts without
giving effect to any choice or conflict of law provision or rule (whether of
the Commonwealth of Massachusetts or any other jurisdiction) that would cause
the application of laws of any jurisdiction other than those of the
Commonwealth of Massachusetts.

 D-1
 

 

IN WITNESS WHEREOF,
Seller and Buyer have caused this instrument to be duly executed under seal as
of and on the date first above written.

	
  

  	
  NITROMED, INC.

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  	 

	
   

  	
  Name:

  	
   

  	 

	
   

  	
  Title:

  	
   

  	 

	
  ACCEPTED:

  	
   

  	
   

  
	
  SHIRE
  HUMAN GENETIC THERAPIES, INC.

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  
	
  Name:

  	
   

  	
   

  
	
  Title:

  	
   

  	
   

  

 

 D-2Exhibit 10.25

[Company Logo]

Cogent Communications

1015 31st Street, NW 
Suite 330

Washington,
DC  20007

Tel:   202-295-4201

Confidential Fax:  
202-342-8269

May 17, 2004

Mr. Jeffrey S. Karnes

47172 Sky Lane

Potomac Falls, Va. 20165

Dear Jeff:

Cogent Communications
is offering you the position of Vice President, Retail Sales. Your monthly
starting salary will be $14,583.33 the equivalent of $175,000 if calculated
annually and $50,000 payable as a commission based upon monthly performance
targets set by the CEO. Your commission, if any, will be paid 32 days following
the end of each quarter. Your initial performance targets will be deemed met
until July 31, 2004. This position is an “exempt” position and will not be
eligible for overtime compensation. You will be an employee at will and may be
discharged at any time without cause. 
Base salary will be paid semi-monthly.

In addition to the
cash compensation you receive, Cogent will grant to you 500 shares of Series H
Preferred Stock which is convertible at the rate of 769 shares of common to one
share of preferred or 384,500 shares of common stock. Twenty-five percent (25%)
of these shares will vest after one year of service and the remainder will vest
monthly over the next three (3) years so that you will be fully vested after
four (4) years of employment.  In order
to receive these shares you must sign Cogent’s standard Restricted Stock
Agreement at the time of your employment. The award of these shares is subject
to approval by the board of directors.

In the event of
Constructive Termination Without Cause, you will be eligible for the benefits
contained in the Severance Agreement attached to this letter.

As a member of
Cogent’s team, you will be entitled to health care and dental coverage, which
is partially (50%) funded by the company. 
The company will also offer a funded life insurance plan.  The company has also implemented a 401(k)
retirement plan that is corporately administered, however, it requires
individual contributions on a non-matching basis by individual
participants.  You will be eligible for 3
weeks paid vacation annually. Additionally, the company has 6 fixed major
holidays and 3 discretionary floating holidays to be chosen by you. These
benefits may be modified by Cogent at any time.

Your employment
date will be on or before June 1, 2004 or at a mutually agreed to date between
yourself and the company.  Also, as a
condition of employment, you will be required to sign Cogent’s standard
agreement providing for invention disclosure and assignment, limitation of your
right to compete with Cogent if you leave, and non-disclosure of confidential
information. Your employment is also contingent upon completing the Form I-9
(Employment Eligibility Verification) and providing the required documentation
establishing your legal right to work in the U. S. on your first day of
employment. Please note that by law, the I-9 requirement must be met before you
can begin work.

We
look forward to having you join our team and build the most advanced next
generation network for high-speed Internet services.  If you have any further questions, please
give me a call at 202-295-4201.

Sincerely,

/s/ David
Schaeffer

Dave Schaeffer

CEO

Accepted

	
  /s/ Jeffrey S. Karnes

  	
   

  	
  5/17/04

  	
   

  	
   

  
	
  Jeffrey S.
  Karnes

  	
   

  	
  Date

  	
   

  	
   

  

 

Severance
Agreement

1.     This agreement is entered into by Cogent
Communications, Inc. (“Cogent”) and the executive employee signing this
Agreement, below (“Executive”).

2.     As an inducement for Executive to focus his
or her full efforts on Cogent’s business without undue concern for future
employment the Compensation Committee of the Cogent Board of Directors has
approved the following minimum severance provisions for Executive.  This severance is not intended to reduce any
severance arrangement provided for in Executive’s offer letter or other
agreement.  In any case in which such
offer letter or other agreement provides a greater severance compensation with
respect to cash payment or continuation of benefits Executive shall receive the
greater cash payment or benefit.

3.     If Executive is terminated other than for
Cause (as defined below) or Executive terminates his or her employment for Good
Reason (as defined below), Executive shall continue to receive his or her
salary (reduced by all mandatory withholdings for taxes or other governmentally
required payments such as garnishments) for 3 months following the date of
termination, i.e. Executive shall be paid through the 91st day following the date of termination.  If such termination follows the 5th anniversary of Executives employment by Cogent
then such payment shall be increased to 6 months salary, i.e. executive will be
paid through the 182nd day following the date of termination.  However, if the termination follows a Change
of Control (as defined below) such payment shall be made as a lump sum within 5
days of termination. Salary means Executive’s salary before voluntary
withholdings and reductions (such as those for parking, 401(k) plan, medical,
dental, and life insurance) and before mandatory withholdings for taxes and
other governmentally required payments such as garnishments.  At the election of Executive, the employee
share of the cost of benefits (provided in paragraph 4) may be paid through a
salary reduction agreement (in order to make such payments with pre-tax
income).  If the amount payable under
this paragraph is less than the amount payable under Executive’s offer letter
or other agreement no payment shall be made under this paragraph and Executive
shall instead receive the payment provided for in the offer letter or other
agreement.

4.     If Executive is terminated other than for
Cause or Executive terminates his or her employment for Good Reason, Executive
shall continue to receive through the last day of the sixth month following the
month in which termination occurs health insurance, dental insurance, life
insurance (to the extent paid by the company), and long term disability
insurance.  Cogent shall pay the company
share of such benefits and Executive shall pay the employee share, e.g. the
employee portion of the premium for health and dental insurance.  The employee share and company share shall be
the same as currently applicable to the benefits at the time of
termination.  If the value of the benefit
under this paragraph is less than the benefit under Executive’s offer letter or
other agreement no benefit shall be provided under this paragraph and Executive
shall instead receive the benefit provided for in the offer letter or other
agreement.

5.     If Executive is terminated other than for
Cause in conjunction with or within 90 days following a Change of Control,
Executive shall on the date of notification of such termination become fully
vested in any restricted stock, options, or other similar incentive plan
involving vesting.

6.     For purposes of this agreement, Cogent
shall have “Cause” to terminate the Executive’s employment hereunder (i) upon
the Executive’s conviction for the commission of an act or acts constituting a
felony under the laws of the United States or any state thereof, or (ii) upon
the Executive’s willful and continued failure to substantially perform his or
her duties hereunder (other than any such failure resulting from the Executive’s
incapacity due to physical or mental illness), after written notice has been
delivered to the Executive by Cogent, which notice specifically identifies the
manner in which the Executive has not substantially performed his duties, and
the Executive’s failure to substantially perform his duties is not cured within
ten (10) business days after notice of such failure has been given to the
Executive. No act or failure to act on the Executive’s part shall be deemed “willful”
unless done or omitted to be done, by the Executive not in good faith and
without reasonable belief that the Executive’s act, or failure to act, was in
the best interest of Cogent.

7.     “Good Reason” shall mean the occurrence
(without the Executive’s express written consent) of any one of the following:

a.               the assignment to Executive of duties inconsistent with the
Executive’s status as a senior executive officer of the Company or a
substantial adverse alteration in the nature or status of the Executive’s
responsibilities; or

b.              if Executive is an attorney, resignation required by any
applicable law, regulation, rule, or code of professional responsibility; or

c.               a reduction in Executive’s salary; or

d.              relocation of Executive’s principal place of employment outside of
the Washington, DC area.

8.      “Change of Control” shall mean any of
the following: (i) a consolidation, merger or reorganization of Cogent
Communications Group, Inc. with or into any other corporation or corporations
in which the stockholders of Cogent Communications Group, Inc. immediately
before such event shall own fifty percent (50%) or less (calculated on an as
converted basis, fully diluted) of the voting securities of the surviving
corporation; (ii) a transaction or series of related transactions, other than
an underwritten public offering, in which at least fifty percent (50%) of
Cogent Communications Group, Inc.’s voting power is transferred; (iii) the
sale, transfer or lease of all or substantially all of the assets of Cogent
Communications Group, Inc.; (iv) the acquisition of shares of capital stock of
Cogent Communications Group, Inc. (whether through a direct issuance by Cogent
Communications Group, Inc., negotiated stock purchase, a tender for such
shares, merger, consolidation or otherwise) by any party or group that did not
beneficially own a majority of the voting power of the outstanding shares of
capital stock of Cogent Communications Group, Inc. immediately prior to such
purchase, the effect of which is that such party or group beneficially owns at
least a majority of such voting power immediately after such event; or (v) the
consummation by Cogent Communications Group, Inc. of a plan of complete
liquidation of Cogent Communications Group, Inc..

9.     Executive’s continued employment shall not
constitute consent to, or a waiver of rights with respect to any act or failure
to act constituting Good Reason hereunder. Notwithstanding the foregoing, a
termination shall not be treated as a Termination for Good Reason if the
Executive shall have consented in writing to the occurrence of the event giving
rise to the claim of Termination for Good Reason.

10.   Executive shall be entitled to the
indemnification set forth in the certificate of organization of any entity for
which he or she performs services to the maximum extent permitted by law.  Executive shall also be entitled to the protection
of any insurance policies Cogent may elect to maintain generally for the
benefit of its directors and officers.

11.   Executive agrees that he or she remains an
employee at will whose employment may be terminated at any time with or without
cause.

12.   Cogent agrees that Executive is giving
consideration for this agreement by accepting employment with Cogent.

 

	
  Accepted and agreed to:

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Cogent
  Communications, Inc.

  	
   

  	
  Executive

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
   

  	
   

  	
   

  	
  Name:

  	
   

  	
   

  
	
  Title:

  	
   

  	
   

  	
   

  	
  Date:

  	
   

  	
   

  
	
  Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]